Introduction
Chronic obstructive pulmonary disease (COPD) is a syndrome characterized and defined by a single physiological parameter: limitation of expiratory air-flow which, most often, is slowly progressive over the years. According to the widely accepted definition from Global Initiative on Obstructive Lung Disease (GOLD) COPD is ''a disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lungs to noxious particles and gases" [44] . COPD is a condition characterized by an abnormal inflammatory response beyond the lungs with evidence of low-grade systemic inflammation which causes systemic manifestations such as weight loss, skeletal muscle dysfunction, an increased risk of cardiovascular disease, osteoporosis and depression, among others [6, 45] . Several studies have shown systemic inflammation in COPD patients with increased neutrophil, macrophage, and T-lymphocyte numbers and high concentrations of inflammatory mediators in peripheral blood (C-reactive protein (CRP) and TNF-a) [11, 1] . Airway inflammatory markers are higher in more severe disease and increase during COPD exacerbations. However, no exhaled biomarker has been widely used in clinical trials in COPD [7] . Kostikas et al. [12] stated that systemic inflammation is present in stable COPD and the intensity of the inflammatory process relates to the severity of the underlying disease. In the interest of improving the diagnosis of COPD, several types of biomarker have been measured that are related to disease pathophysiology and the inflammatory and destructive process in the lung. However, there is little information about biomarker reproducibility and the relationship with disease development, severity, or progression [9] . Several inflammatory markers such as C-reactive protein (CRP), fibrinogen and IL-6, are increased in patients with COPD in both stable disease and exacerbations, with CRP being the most studied biomarker [5] . One of the inflammatory markers which is increasingly evaluated in COPD patients is CRP. CRP is an acute phase protein synthesized predominantly by the hepatocytes in response to tissue damage or inflammation. It has been accepted that levels of CRP relate to the presence of airflow obstruction [44] . Very little is known about the mechanism of increased TNF-a concentration in the plasma of COPD patients and its relationship with disease severity and active smoking has not been established [9, 15] . Tobacco smoking is the main risk factor of chronic obstructive pulmonary disease (COPD) but not all smokers develop the disease. An abnormal pulmonary and systemic inflammatory response to smoking is thought to play a major pathogenic role in COPD, but this has never been tested directly. Yet, only a proportion of smokers, so called ''susceptible smokers'', develop the disease [42, 3] . The genetic and epigenetic background of each smoker is likely to regulate the type and intensity of his/her inflammatory response to smoking [10] . In ''susceptible smokers'', this response is thought to be ''enhanced'', both in the lungs and in the systemic circulation, and is believed to drive disease progression [41] . However, despite the wide acceptance of this notion, no previous study has actually studied the ''response'' to smoking (i.e., the specific inflammatory changes that occur before and after smoking) in susceptible smokers (i.e., patients with COPD) and resistant smokers (i.e., smokers with normal spirometry) [3] . Long-term smoking causes airway inflammation characterized by neutrophil, macrophage, and activated T lymphocyte infiltration and by increased cytokine concentrations such as tumor necrosis factor-alpha (TNF-a), interleukins (IL)-6 and IL-8 [4, 2, 14] . Although nearly all smokers show some evidence of lung and systemic cellular and/or humoral inflammation, only a few will suffer an amplified response and develop COPD. The aim of this study was to identify whether the inflammatory process in stable COPD patients is powerful enough to produce significant changes in the selected inflammatory markers (TNF-a and hs CRP). The role and levels of TNF-a and hs CRP in the peripheral circulation of COPD patients and the relationship between these biomarkers with prognostic factors in COPD will be investigated and as we hypothesized that smoking exposure will induce a different inflammatory signature, the impact of smoking on inflammatory biomarkers in patients with chronic obstructive pulmonary disease will be evaluated. With the development of many new drugs that target inflammation in COPD, there is a pressing need to identify reliable biomarkers that may indicate whether an anti inflammatory therapy is likely to have clinical benefit. A major problem is the lack of any gold standard anti inflammatory therapy that is effective in COPD, as a yardstick to compare potential therapies.
Methods
This case-control observational prospective study was conducted on fifty-eight clinically stable COPD patients (26 nonsmokers and 32 current smokers; at different stages ranged from mild to very severe one, their mean age 53.1 ± 14.25 and 53.9 ± 5.95 years respectively), recruited from Chest Department, Assiut University Hospitals. All patients met the Global Initiative for Obstructive Lung Disease (GOLD) [4] recommended spirometric criteria for COPD (ratio of post-bronchodilator forced expiratory volume in one second [FEV1] to forced vital capacity [FVC] less than 70%) [17] . The COPD patients were subdivided according to their treatment into: thirteen patients use only short acting bronchodilator as needed, the remaining forty five patients were using long-term bronchodilators from those 45 patients, twenty seven (13 COPD current smokers and 14 non-smokers) patients were regularly using inhaled corticosteroid (800 mcg of budesonide), sixteen patients of them had been on stable oxygen flow therapy for the last six months. No patients were medicated with theophylline or leukotriene modifiers.
Patients on oral steroid use or exacerbations in the last three months before enrollment in the study, or diagnosed with other respiratory disease like asthma, bronchiectasis, bronchiolitis or tuberculosis, or presence of other chronic diseases like diabetes, renal failure, and cancer were excluded. In addition, age, sex and BMI matched apparently healthy subjects with no evidence of COPD or using regular medications for other diseases from medical stuff and families who underwent health examination at Assuit university hospitals were enrolled in the study as control group; the controls were subdivided into fifteen current smoker controls (at least 10 pack-years) and fifteen never-smoker controls. All participants were subjected to thorough history taking, full clinical examination, anthropometric measurements with chest X-ray and spirometry. Forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) were obtained from the flowvolume curve using a spirometer [Conventional spirometry was a 10-Lclosed circuit Spirographs (Zan 300, Sensor Medics MGA USB, Germany)] to study patients and control groups. Static lung volumes were measured by closed-circuit helium dilution method. The reference values used were those of the American Thoracic Society standards) before and 20 min after b-agonist (fenoterol 400 mcg) inhalation. The highest value of at least three measurements was selected and expressed as a percentage of reference values [18] . Venous blood samples were collected from participants under standardized conditions. Samples were centrifuged (3000g for 10 min) and serum samples were divided and stored in aliquots at -20°C until analysis. Peripheral hemogram, liver function tests, kidney function tests, High sensitivity C-reactive protein (hs-CRP) measurement was done by Accu-Bind ELISA Microwells (Monobind Inc., USA code 3125-300A lot EIA-31KIC2). Assay of serum levels of TNF-a was performed using AviBion Human TNF-a ELISA Kit (Orgenium, Finland, Rev 02.10).
Smoking history was calculated in pack-years as the product of tobacco use (i current smoker n years) and the average number of cigarettes smoked per day/20 (years Â cig. per day/20). The study was approved by the Institutional Ethics Committee of Faculty of Medicine, Assiut University and written informed consent was obtained from each participant.
Statistical analysis
Data were analyzed with Statistical package for social sciences (SPSS) version 17 Chicago USA. Data were expressed as mean ± SD or mean ± SE and frequencies according if they are quantitative or qualitative respectively. Non-parametric tests were used in the current study.
(1) Mann-Whitney Test (equivalent to independent Student's t test in parametric tests) was used for comparison of quantitative variables among two independent groups. (2) Wilcoxon Signed Ranks Test (equivalent to paired t test in parametric tests) was used for comparison of quantitative variables among two dependent groups. (3) Chi-Square Test was used for comparison of distribution of qualitative variables among different groups. (4) Comparisons between groups were achieved by Kruskal-Wallis Test (equivalent to one way ANOVA test). (5) Correlation between continuous variables was performed using Spearman's correlation coefficient.
P value < 0.05 is considered statistically significant. Multiple regression analysis was used to determine independent factors affecting dependent variables.
Results
Demographics, baseline lung function, and body mass index of COPD and controls according to the smoking status of the smokers are presented in Table 1 where it shows COPD patients tended to have a nearly same age to controls regardless their smoking status with similar smoking history (pack-years) in current smoker COPD patients and controls. As expected, COPD patients had significant severe airflow limitation and decreased SpO 2 with highly significant decline in FEV1 compared to controls. Tables 2a, 2b, Tables 3a, 3b and Figs. 1 and 2 show highly significant elevated levels of circulating TNF-a and hs-CRP in COPD patients in comparison to the control group regardless of their smoking status with significantly high levels in current smoker patients and controls. Table 4 shows the significant increased levels of the TNF-a with the increased severity of COPD and increased grade of dyspnea. Moreover, non significant differences for the measured TNF-a were found between the patients according to the use of the inhaled corticosteroid therapy.
The regression results showed a highly significant positive association among the measured TNF-a with smoking index, increased degree of dyspnea and degree of COPD, while a non significant positive association among the measured hs-CRP with increased degree of dyspnea and degree of COPD with a highly significant positive association among the measured hs-CRP with smoking index is found in Table 5 . Table 6 shows highly significant positive associations among the measured TNF-a and hs-CRP with smoking index in COPD patients and current smoker controls. Table 7 shows highly significant positive associations among the measured TNF-a levels with FEV1 in COPD patients and controls regardless of their smoking status. However, regarding the smoking status in COPD patients, there was a highly significant positive association among current smokers with no significant difference among the non smokers between FEV1 with the measured hs-CRP. In controls regardless of their smoking status highly significant positive associations among the measured hs-CRP with FEV1 were detected.
Discussion
Chronic obstructive pulmonary disease (COPD) is a slowly progressive disease induced primarily by smoking tobacco. Other etiological factors of COPD, like air pollution, poor nutrition, professional risk at work and genetic factors may have probably participated. The pathophysiology of COPD is not completely understood. [45] . According to Global Initiative on Obstructive Lung Disease (GOLD) definition, ''the airflow limitation in COPD is not fully reversible and is usually progressive and associated with an abnormal inflammatory response of the lungs to noxious particles and gases" [44] . In the interest of improving the diagnosis of COPD, several types of biomarkers have been measured that are related to disease pathophysiology and the inflammatory and destructive process in the lung. The aim of this study was to identify whether the inflammatory process in stable COPD patients is powerful enough to produce significant changes in the selected inflammatory markers (TNF-a and hs CRP) and to evaluate the relationship between systemic inflammation and smoking status in COPD patients.
CRP is an acute phase protein synthesized predominantly by the hepatocytes in response to tissue damage or inflammation. It has been accepted that levels of CRP relate to the presence of airflow obstruction. Elevated CRP has been known to be used as a surrogate marker of systemic inflammation in diverse conditions [44] . Interestingly, our study in fact, showed that the serum level of hs CRP was highly significantly elevated in COPD patients compared with controls regardless of their smoking status. This result confirms that the higher levels of circulating hs CRP may be thus regarded as a valid biomarker of low-grade systemic inflammation in the COPD. Our results were in agreement with [43] who reported that COPD patients had higher levels of hs-CRP due to the fact of the earlier response of hs-CRP, as it is secreted as acute phase reactants by the liver in response to IL-6. Moreover, [8, 11, 1] stated that systemic inflammation in COPD patients is associated with increased neutrophil, macrophage, and T-lymphocyte numbers and high concentrations of inflammatory mediators in peripheral blood (C-reactive protein (CRP) and TNF-a). Their study showed a significantly higher levels of circulating hs CRP in COPD patients than in smoking and non smoking controls. However, the level of hs CRP in the smoking COPD population remained non significantly higher than in the nonsmoking patients. We suggest that, although cigarette smoking has a role in promoting inflammatory process in COPD patients, it is not the leading cause of increased inflammatory markers. it should be noticed that only some cases develop inflammatory reaction following cigarette smoking, and this can be due to genetic differences. In contrast to the above findings, [44] , showed the level of hs CRP in the smoking COPD population remained significantly higher than in the non-smoking patients. TNF-a, a powerful pro-inflammatory cytokine primarily produced by activated macrophages, is thought to a critical role in the pathogenesis of COPD by promoting and maintaining the expression and release of various proinflammatory mediators which lead to tissue damage and remodeling [13] . Very little is known about the mechanism of increased TNF-a concentration in the plasma of COPD patients and its relationship with disease severity and active smoking has not been established [9, 15] . However, Marevic et al., 2008 reported that tobacco smoking induces the release of TNF-a and has an important role in the pathophysiology of COPD. TNF-a influences the gene expression of interleukin-8 and endothelin-1 (ET-1) in human endothelial cells, and participates in bronchoconstriction through secondary release of ET-1.
Our study showed that the level of serum inflammatory marker; TNF-a was highly significantly elevated in COPD patients regardless of their smoking status indicating a persistent systemic inflammation in subjects with COPD with significantly high levels of TNF-a in current COPD smokers. These results suggest that smoking may be associated with higher TNF-a mediated systemic inflammation in COPD patients. These findings were in agreement with [13] who reported the increased levels of serum TNF-a, IL-6 and tissue inhibitors of metalloproteinase-1 in asthma and COPD patients with highest levels in current smoker COPD patients and controls. Moreover, our results were in consistent with those of [11, 1] , Marevic et al., 2008, [45] who reported a significant increase in serum inflammatory markers TNF-a, hs CRP and interlukin-6 in different stages of COPD patients and this increment was significantly higher than those of the controls. We may thus speculate the association of smoking with higher systemic TNF-a levels observed in this study may partially explain some benefits associated with smoking cessation. In contrast to our findings, Vernooy et al. [17] reported an increase in the concentration of soluble TNF-a receptors, while the concentration of TNF-a was within the reference range for healthy individuals. Possible explanation for unchanged concentration of TNF-a is its local and short term effects, its degradation and its half life of approximately 6-7 min, as well as its binding to receptors and renal clearance.
FEV1 is easily measured and is a spirometric predictor of mortality in patients with COPD. Factors that affect the decline of FEV1 are, therefore, of prognostic importance in COPD [45] . Our study revealed the increased TNF-a levels in COPD patients with increased airway obstruction severity, increased and degree of dyspnea with a significant negative correlation between TNF-a with FEV1. These results clearly confirm the fact that the intensity of the inflammatory process in COPD could be related to the severity of the underlying disease. Our findings were in agreement with [40] who stated the higher serum TNF-a levels in COPD patients were associated with patients with severe COPD in comparison with mild-moderate COPD patients. Furthermore, Kostikas et al. [12] and Samy et al. [45] reported TNF-a levels increased according to the stage of the COPD. Interestingly, non significant higher hs-CRP concentrations associated with increased severity of airway obstruction and an increased degree of dyspnea were observed in our study. These findings were in agreement with [37, 15] who reported that higher hs-CRP concentration has been associated with airway obstruction severity, increased resting energy expenditure, and impaired exercise capacity and quality of life in COPD patients [44] concluded that the circulating levels of the inflammatory marker hs-CRP are significantly elevated in patients with COPD, supporting the view that COPD is in part an inflammatory disorder. Hs-CRP levels in stable COPD patients are best correlated with FEV1 and 6-minute walk distance (6MWD). Clearly, in the our study hs CRP levels were inversely correlated with FEV1 in stable COPD patients. The strongest negative association between FEV1 and CRP and higher CRP levels over time were associated with a faster FEV1 decline. These results were consistent with those of Man et al., 2006 and [44] who stated CRP levels associated with accelerated decline in FEV1 and mortality in patients with mild to moderate COPD, indicating that CRP measurements might enable identification of patients at high risk of disease progression and mortality.
Tobacco smoking is the main risk factor of chronic obstructive pulmonary disease (COPD) but not all smokers develop the disease. An abnormal pulmonary and systemic inflammatory response to smoking is thought to play a major pathogenic role in COPD, but this has never been tested directly. Long-term smoking causes airway inflammation characterized by neutrophil, macrophage, and activated T lymphocyte infiltration and by increased cytokine concentrations such as tumor necrosis factor-alpha (TNF-a), interleukins (IL)-6 and IL-8 [4, 2] . Although nearly all smokers show some evidence of lung and systemic cellular and/or humeral inflammation, only a few will suffer an amplified response and develop COPD.
Interestingly, highly significant higher concentrations of TNF-a and hs-CRP in COPD patients associated with an increased severity of smoking status were observed in our study. The correlations of TNF-a and hs CRP concentration with smoking habit (pack/years) supports the assumption that tobacco smoke has an influence on systemic inflammation. Hs-CRP and TNF-a indicate that COPD is a systemic inflammatory disease, and they could serve as predictors for exacerbations. However, it is unclear whether established inflammation in smokers returns to normal after smoking cessation. Smoking cessation is the only management measure associated with reduced FEV1 decline in COPD patients; however, to date, no reduction in airway inflammation has been demonstrated when ex-smokers are compared to current smokers by Gamble et al. [2] who did not find any differences in cell counts or inflammatory markers (CD8+, CD4+, CD 68+, or TNF-a) in bronchial biopsies of COPD current smokers and COPD ex-smokers. Nevertheless, [33] reported that neutrophil and lymphocyte numbers, and IL-8 concentration in the sputum of COPD patients were increased one year after smoking cessation.
Unfortunately, we could not reveal the influence of inhaled corticosteroids on systemic inflammation in COPD patients owing to small sized sample used, more researches with larger sample size and longer observation time needed to detect potential differences and to confirm these results.
Conclusions
The circulating levels of the inflammatory markers hs-CRP and TNF-alpha are significantly elevated in patients with COPD, supporting the view that COPD is in part an inflammatory disorder. These circulating biomarkers in stable COPD patients are best correlated with FEV1 suggesting that these circulating biomarkers are good candidates as predictors for rapid decline of FEV1 in COPD, although a larger size study with a longer term observation is needed to confirm these findings. It is likely that in the future biomarkers will become increasingly required to aid in determining those patients who will benefit from a given drug therapy to improve risk and/or cost benefit, especially since it is becoming more widely considered in COPD. Smoking is associated with higher levels of TNF-alpha and hs-CRP mediated systemic inflammation in patients with or without COPD, therefore active smoking maybe associated with even a higher degree of the systemic inflammation. Longitudinal studies evaluating the effects of smoking cessation on bronchial and systemic inflammation are needed to allow better understanding of these relationships and their consequences.
